LEX Diagnostics is a privately held molecular diagnostics company developing products designed to enhance patient care by delivering clinical insights within minutes and at the time they are most valuable. Delivering a high-speed molecular test will redefine point-of-care diagnostics.

Our ultra-fast thermal cycling technology delivers sensitive PCR results directly from a swab sample in a user-friendly system. The LEX Diagnostics system fits seamlessly into primary care workflows, bringing the sensitivity of PCR to urgent care centres, physician’s office labs and pharmacies and at a much lower cost per test than competing molecular offerings.

History

LEX Diagnostics Ltd was founded in 2020, as a spin out from TTP plc, a leading life sciences technology and product development company founded in 1988 and active in the development of point-of-care diagnostics for more than 20 years.

We are based on the Melbourn Science Park, near Cambridge, UK.

2024

Spring 2024 – LEX takes delivery of final pre-production prototypes

Spring 2024 – Team size increasing with focus on completing development and preparations for clinical studies.

2023

January 2023 – LEX appoints Ed Farrell as its new CEO

Building the team for the next stage in our journey.

Winter 2023 – LEX secures significant funding with a third party investor

November 2023 – LEX takes delivery of its near final prototypes

July 2023 – LEX appoints Heather Danks as its CTO

2022

August 2022 – Commences ISO13485 certification activities

Appoints experienced Quality Manager to guide and support the team as we prepare for ISO13485 certification.

2022: Reagent production laboratory and lyophilisation capacity expanded

Enhances in-house reagent lyophilisation capacity to support the demand of a growing R&D programme.

April 2022 – Reagent production laboratory and lyophilisation capacity expanded

Enhances in-house reagent lyophilisation capacity to support the demand of a growing R&D programme.

2021

September 2021 – LEX receives core patent grant from USPTO

The core innovation making 5 minute sample-to-answer possible is secured.

May 2021 – LEX establishes 100k/yr manufacturing line for its consumables

Secures supply for development and clinical studies and starts the journey towards high volume manufacturing.

2020

September 2020 – LEX expands the scientific team and builds new facilities

Grows and brings in-house key capabilities including custom reagent development, bioinformatics and the
manufacture of medical consumables.

February 2020 – LEX Diagnostics Ltd founded as an independent company within the TTP Group

Following successful technology demonstration TTP Group invests core intellectual property and key staff into a dedicated company with a mission to commercialise an ultrafast point-of-care diagnostic for respiratory viruses.

2018

July 2018 – Invention of ultra-fast thermal cycling technology

An internal TTP project invents a low cost, rapid thermocycling technology based on the understanding that PCR speed is not limited by biology, but by thermal cycling speed